Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
Harry P. Erba, Hamid Sayar, Mark Juckett, Michael Lahn, Valerie Andre, Sophie Callies, Shelly Schmidt, Sunil Kadam, John T. Brandt, Dirk Van Bockstaele, Michael Andreeff…show all 11hideVolume:
31
Language:
english
DOI:
10.1007/s10637-013-9935-x
Date:
August, 2013
File:
PDF, 425 KB
english, 2013
File converter
More search results
More benefits 
